Pharmaceutical company Sosei has launched new companies using technology from its 2015 acquisition of Heptares, both of which have received funding from Medicxi.

Japan-based pharmaceutical company Sosei has partnered healthcare venture capital fund Medicxi to form two new independent companies focused on treating neurological diseases. Medicxi is investing a total of €40m ($45.8m) in the two companies, Orexia and Inexia, which are working on therapies meant to combat neurological diseases by altering G protein-coupled receptors Orexin OX1 and OX2.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.